Login to Your Account



Antigenics Gets FDA Clearance, Resumes Oncophage Enrollment

By Kim Coghill


Tuesday, November 25, 2003
The FDA gave Antigenics Inc. the go-ahead to resume enrollment of two Phase III trials for the personalized cancer vaccine Oncophage, following a 13-week partial clinical hold. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription